
    
      The primary objective of this study is to examine the efficacy of CX157 Modified Release
      Tablet, 125 mg administered twice per day (BID) as compared to placebo in subjects with
      Treatment Resistant Depression (TRD). Secondary objectives are to evaluate the safety and
      tolerability of CX157 Modified Release Tablet, 125 mg BID in TRD subjects and characterize
      steady-state pharmacokinetic profile and explore pharmacodynamic relationships.
    
  